Opinion: Is the Sputnik V vaccine too good to be true? Without the data, it’s hard to know
Sputnik V, the Covid-19 developed by the Moscow-based Gamaleya Research Institute, was the early rising star of Covid-19 vaccines. Now it is mired in controversy arising from the institute’s failure to share data about the vaccine.
After being developed, authorized, and administered at breakneck speed, it is now being rolled out in 39 countries and due to be rolled out in 27 more — with a combined population of more than 3.2 billion people. These are mainly lower- and middle-income countries that lost out to countries in Western Europe and North America in the race to secure sufficient vaccine doses to protect their populations.
